TY - JOUR
T1 - The effect of silymarin on plasma levels of malon-dialdehyde in patients receiving long-term treatment with psychotropic drugs
AU - Palasciano, Giuseppe
AU - Portincasa, Piero
AU - Palmieri, Vincenzo
AU - Ciani, Daniela
AU - Vendemiale, Gianluigi
AU - Altomare, Emanuele
PY - 1994
Y1 - 1994
N2 - The efficacy of the antioxidant silymarin in preventing psychotropic drug-induced hepatic damage was evaluated in a double-blind, placebo-controlled study. Sixty patients receiving chronic psychotropic drug therapy were randomly divided into four groups and were treated for 90 days with silymarin or placebo as follows: group IA-treatment with psychotropic drugs and silymarin, 800 mg/d; group IB-treatment with psychotropic drugs and placebo; group IIA-suspension of psychotropic drugs plus treatment with silymarin, 800 mg/d; and group IIB-suspension of psychotropic drugs plus treatment with placebo. Serum levels of malon-dialdehyde (the end product of the oxidation of polyunsaturated fatty acids) and the indices of hepatocellular function were assessed in each patient at baseline (day 0), on days 15, 30, 60, and 90, and 1 month after the completion of treatment. Our data show that silymarin, when used at submaximal doses, reduces the lipoperoxidative hepatic damage that occurs during treatment with butyrophenones or phenothiazines. The study results also suggest that increased lipoperoxidation may contribute to psychotropic drug-induced hepatotoxicity.
AB - The efficacy of the antioxidant silymarin in preventing psychotropic drug-induced hepatic damage was evaluated in a double-blind, placebo-controlled study. Sixty patients receiving chronic psychotropic drug therapy were randomly divided into four groups and were treated for 90 days with silymarin or placebo as follows: group IA-treatment with psychotropic drugs and silymarin, 800 mg/d; group IB-treatment with psychotropic drugs and placebo; group IIA-suspension of psychotropic drugs plus treatment with silymarin, 800 mg/d; and group IIB-suspension of psychotropic drugs plus treatment with placebo. Serum levels of malon-dialdehyde (the end product of the oxidation of polyunsaturated fatty acids) and the indices of hepatocellular function were assessed in each patient at baseline (day 0), on days 15, 30, 60, and 90, and 1 month after the completion of treatment. Our data show that silymarin, when used at submaximal doses, reduces the lipoperoxidative hepatic damage that occurs during treatment with butyrophenones or phenothiazines. The study results also suggest that increased lipoperoxidation may contribute to psychotropic drug-induced hepatotoxicity.
UR - http://www.scopus.com/inward/record.url?scp=0028332566&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028332566&partnerID=8YFLogxK
U2 - 10.1016/S0011-393X(05)80184-5
DO - 10.1016/S0011-393X(05)80184-5
M3 - Article
AN - SCOPUS:0028332566
VL - 55
SP - 537
EP - 545
JO - Current Therapeutic Research - Clinical and Experimental
JF - Current Therapeutic Research - Clinical and Experimental
SN - 0011-393X
IS - 5
ER -